Inactief instrument

Andere talen BioLineRx Ltd. TEL AVIV STOCK EXCHANGE

Aandelen

BLRX

IL0011015182

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapy Applications in Sickle Cell Disease	31/05
BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease	30/05
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	29/05
BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	28/05
BioLineRx Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	28/05
BioLineRx Ltd. announced that it has received $26 million in funding from Kreos Capital Management (UK) Limited	28/05
BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology	24/05
BioLineRx to Report First Quarter 2024 Results on May 28, 2024	22/05
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification	20/05
BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	06/05
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17/04
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17/04
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10/04
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10/04
BioLineRx Announces $6 Million Registered Direct Offering	02/04
BioLineRx Shares Fall After $6 Million Registered Direct Offering	01/04
BioLineRx : Form 20-F/A (Amendment No. 1	28/03
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	27/03
BioLineRx : Annual Report on Form 20-F FOR 2023	26/03
BioLineRx : Report of Periodic or Interim Report	26/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BioLineRx Ltd. TEL AVIV STOCK EXCHANGE

Aandelen

BLRX

IL0011015182

Andere talen

Filters